SNMMI 2026
ITM SNMMI 2026 Dinner Symposium
The Evolution of SSTR-Targeted Therapy - From agonists to antagonists and emerging radionuclides
May 31 2026 | 6:30 - 7:30 PM
Petree Hall C
LA Convention Center
Los Angeles, CA
Dr. Julia Fricke, MD
Objective:
Discuss the evolution of SSTR-targeted radiopharmaceutical therapy; spanning early approaches, current 177Lu agonist therapies (including 177Lu-edotreotide and COMPETE data), to next-generation ligand biology and emerging radionuclides - linking today's clinical practice with future therapeutic directions.
177Lu-Edotreotide is an investigational product pending review by the U.S. Food and Drug Administration (FDA) and is not approved by any regulatory authority for the safety and/or efficacy of any intended use.
Attendance is free for all SNMMI Annual Meeting Attendees
For more information click here Satellite Symposia | SNMMI Annual Meeting